rewirebio.iobenchmarks
Source

Performance and its limits in rigid body protein-protein docking

Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597

DOI: 10.1016/j.str.2020.06.006Original source

What this source contributed

Records in this release that cite this source. A record can cite several sources.

Results

Values as the source printed them. Compare results only under compatible protocols, datasets and metrics.

Model or configurationMetricValueDatasetEvaluation
ClusPro BM5 Table1 category-routingCAPRI top-10 success rate17.65% percentBM5 evaluated difficult cohortClusPro BM5 difficult top10
ClusPro BM5 Table1 category-routingCAPRI top-30 success rate26.47% percentBM5 evaluated difficult cohortClusPro BM5 difficult top30
ClusPro BM5 Table1 category-routingCAPRI top-10 success rate51.68% percentBM5 evaluated easy cohortClusPro BM5 easy top10
ClusPro BM5 Table1 category-routingCAPRI top-30 success rate63.09% percentBM5 evaluated easy cohortClusPro BM5 easy top30
ClusPro BM5 Table1 category-routingCAPRI top-10 success rate31.82% percentBM5 evaluated intermediate cohortClusPro BM5 intermediate top10
ClusPro BM5 Table1 category-routingCAPRI top-30 success rate36.36% percentBM5 evaluated intermediate cohortClusPro BM5 intermediate top30
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (all targets)7 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (by difficulty category)0 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (by difficulty category)7 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (by difficulty category)N/A countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI high-quality targets (by difficulty category)0 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI high-quality targets (by difficulty category)2 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI medium targets (difficult (flexible) targets; top 10 models; medium (**) as printed, overlap with high not stated)0 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI medium targets (easy (rigid-body) targets; top 10 models; medium (**) as printed, overlap with high not stated)4 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI top-10 success rate58.33% percentBM5 Bound antibody Table1 cohortClusPro Bound antibody top10
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (all targets)10 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (by difficulty category)0 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (by difficulty category)10 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI acceptable targets (by difficulty category)N/A countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI high-quality targets (by difficulty category)0 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI high-quality targets (by difficulty category)3 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI medium targets (difficult (flexible) targets; top 30 models; medium (**) as printed, overlap with high not stated)0 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI medium targets (easy (rigid-body) targets; top 30 models; medium (**) as printed, overlap with high not stated)6 countBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 antibodyCAPRI top-30 success rate83.33% percentBM5 Bound antibody Table1 cohortClusPro Bound antibody top30
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (all targets)51 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (by difficulty category)3 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (by difficulty category)44 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (by difficulty category)4 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI high-quality targets (by difficulty category)0 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI high-quality targets (by difficulty category)2 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI high-quality targets (by difficulty category)0 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI medium targets (difficult (flexible) targets; top 10 models; medium (**) as printed, overlap with high not stated)1 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI medium targets (easy (rigid-body) targets; top 10 models; medium (**) as printed, overlap with high not stated)18 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI medium targets (intermediate targets; top 10 models; medium (**) as printed, overlap with high not stated)2 countBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI top-10 success rate57.95% percentBM5 Enzyme Table1 cohortClusPro Enzyme top10
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (all targets)59 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (by difficulty category)4 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (by difficulty category)50 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI acceptable targets (by difficulty category)5 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI high-quality targets (by difficulty category)0 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI high-quality targets (by difficulty category)2 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI high-quality targets (by difficulty category)0 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI medium targets (difficult (flexible) targets; top 30 models; medium (**) as printed, overlap with high not stated)2 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI medium targets (easy (rigid-body) targets; top 30 models; medium (**) as printed, overlap with high not stated)21 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI medium targets (intermediate targets; top 30 models; medium (**) as printed, overlap with high not stated)2 countBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 enzyme-balancedCAPRI top-30 success rate67.04% percentBM5 Enzyme Table1 cohortClusPro Enzyme top30
ClusPro BM5 Table1 othersCAPRI acceptable targets (all targets)27 countBM5 Others Table1 cohortClusPro Others top10
ClusPro BM5 Table1 othersCAPRI acceptable targets (by difficulty category)3 countBM5 Others Table1 cohortClusPro Others top10
ClusPro BM5 Table1 othersCAPRI acceptable targets (by difficulty category)15 countBM5 Others Table1 cohortClusPro Others top10
ClusPro BM5 Table1 othersCAPRI acceptable targets (by difficulty category)9 countBM5 Others Table1 cohortClusPro Others top10

Claims

Statements this source supports, each with where in the source it was checked.

Models, benchmarks and other records

Methods (1)

Configurations (4)

Benchmarks (1)

Protocols (16)

Dataset subsets (8)

Baselines (5)

Evaluations (16)

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

16 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Artifact SHA-256
1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_sha256

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Artifact url
https://pmc.ncbi.nlm.nih.gov/articles/PMC7484347/
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.artifact_url

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Doi
10.1016/j.str.2020.06.006
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.doi

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieval note
Direct PMC HTML retrieval succeeded; EuropePMC fullTextXML returned HTTP500. Web-tool PMC open returned browser-verification placeholder. Exact retrieved HTML is archived locally for audit.
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieval_note

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Retrieved at
2026-09-30T21:50:23.483497+00:00
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.retrieved_at

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Review method
1 values
  • automated-source-review
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.review.method

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Review: scope
Complete Table1 transcription; protocol inputs and modes from Results and STAR Methods.
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.review.scope

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Url
https://pmc.ncbi.nlm.nih.gov/articles/PMC7484347/
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.url

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Version
Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: attributes.version

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Description
2020 ClusPro BM5 primary author manuscript; Table 1 and STAR Methods.
Source metadata
Performance and its limits in rigid body protein-protein docking

Original source ↗

No field-specific location recorded

Version: Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
Retrieved: 2026-09-30T21:50:23.483497+00:00

catalogued

No individual claim review recorded

Audit details

Field: description

Source artifact SHA-256: 1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

2020 ClusPro BM5 primary author manuscript; Table 1 and STAR Methods.

Release history

No supporting source is linked yet.

Read original source

Download this release (gzip)
Technical metadata and extraction receipts

Stable ID: ucc-docking-cluspro-bm5-2020-source

areas
proteins-complexes
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC7484347/
artifact url
https://pmc.ncbi.nlm.nih.gov/articles/PMC7484347/
doi
10.1016/j.str.2020.06.006
version
Structure 28(9):1071–1081.e3; 2020; PMC author manuscript NIHMS1608597
retrieved at
2026-09-30T21:50:23.483497+00:00
artifact sha256
1c02bd7c53eb0e5d5c243b5e6da23168eb20bcc32ab970719666a5838fd58443
retrieval note
Direct PMC HTML retrieval succeeded; EuropePMC fullTextXML returned HTTP500. Web-tool PMC open returned browser-verification placeholder. Exact retrieved HTML is archived locally for audit.
review
scope: Complete Table1 transcription; protocol inputs and modes from Results and STAR Methods.; method: automated-source-review
Related records

    Suggest a correction